Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Trading 10.1% Higher – Time to Buy?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF)’s share price traded up 10.1% during trading on Wednesday . The company traded as high as $29.79 and last traded at $29.79. 300 shares traded hands during mid-day trading, an increase of 210% from the average session volume of 97 shares. The stock had previously closed at $27.06.

Swedish Orphan Biovitrum Stock Up 10.1%

The company has a quick ratio of 0.71, a current ratio of 1.04 and a debt-to-equity ratio of 0.31. The stock has a 50 day simple moving average of $30.08 and a 200 day simple moving average of $29.31. The stock has a market cap of $10.61 billion, a price-to-earnings ratio of 28.10 and a beta of 0.42.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. Swedish Orphan Biovitrum had a return on equity of 10.54% and a net margin of 15.07%. The firm had revenue of $641.33 million during the quarter, compared to analysts’ expectations of $644.12 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.